Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke
Authors: Raed A. Joundi, Eric E. Smith, Aravind Ganesh, Raul G. Nogueira, Ryan A. McTaggart, Andrew M. Demchuk, Alexandre Y. Poppe, Jeremy L. Rempel, Thalia S. Field, Dar Dowlatshahi, Jim Sahlas, Richard Swartz, Ruchir Shah, Eric Sauvageau, Volker Puetz, Frank L. Silver, Bruce Campbell, René Chapot, Michael Tymianski, Mayank Goyal, Michael D. Hill, Demchuk Andrew M, Buck Brian H, Butcher Kennth S, Phillips Stephn J, Mandzia Jennifer L, Mayich Michael, Poppe Alexandre Y, Roy Daniel, Teitelbaum Jeanne, Dowlatshahi Dar, Kelly Michael E, Silver Frank L, Bharatha Aditya, Camden Marie-Christine, van Adel Brian A, Sahlas Demetrios J, Field Thalia S, Swartz Richard H, Shah Ruchir A, Frei Donald F, Choe Hana, Jadhav Ashutosh, Parrella David T, McDougall Cameron G, Starkman Sidney, Heck Donald, McTaggart Ryan A, Lopez George A, Sauvageau Eric, Nogueira Raul, Puri Ajit S, English Joey D, Martin Coleman O, Schindler Joseph L, Tarpley Jason W, Gupta Rishi, Budzik Ronald F, Bang Oh Young, Heo Ji Heo, Rha Joung-Ho, Sohn Sung-Il, Kim Chang-Hyun, Campbell Bruce CV, Kleinig Timothy J, Thornton John, Murphy Sean, Burns Paul A, Holmin Staffan, Thomalla Götz, Puetz Volker, Psychogios Marios-Nikos, Chapot René, Nagel Simon, Hill Michael D, Goyal Mayank, Menon Bijoy K
Journal: JAMA Neurology (2024)

Importance The time-benefit association of endovascular thrombectomy (EVT) in ischemic stroke with patient-reported outcomes is unknown. Objective To assess the time-dependent association of EVT with self-reported quality of life in patients with acute ischemic stroke. Design, Setting, and Participants Data were used from the Safety and Efficacy of Nerinetide in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1) trial, which tested the effect of nerinetide on functional outcomes in patients with large vessel occlusion undergoing EVT and enrolled patients from March 1, 2017, to August 12, 2019. The ESCAPE-NA1 trial was an international randomized clinical trial that recruited patients from 7 countries. Patients with EuroQol 5-dimension 5-level (EQ-5D-5L) index values at 90 days and survivors with complete domain scores were included in the current study. Data were analyzed from July to September 2023. Exposure Hospital arrival to arterial puncture time and other time metrics. Main Outcomes and Measures EQ-5D-5L index scores were calculated at 90 days using country-specific value sets. The association between time from hospital arrival to EVT arterial-access (door-to-puncture) and EQ-5D-5L index score, quality-adjusted life years, and visual analog scale (EQ-VAS) were evaluated using quantile regression, adjusting for age, sex, stroke severity, stroke imaging, wake-up stroke, alteplase, and nerinetide treatment and accounting for clustering by site. Using logistic regression, the association between door-to-puncture time and reporting no or slight symptoms (compared with moderate, severe, or extreme problems) was determined in each domain (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) or across all domains. Time from stroke onset was also evaluated, and missing data were imputed in sensitivity analyses. Results Among 1105 patients in the ESCAPE-NA1 trial, there were 1043 patients with EQ-5D-5L index values at 90 days, among whom 147 had died and were given a score of 0, and 1039 patients (mean [SD] age, 69.0 [13.7] years; 527 male [50.7%]) in the final analysis as 4 did not receive EVT. There were 896 survivors with complete domain scores at 90 days. There was a strong association between door-to-puncture time and EQ-5D-5L index score (increase of 0.03; 95% CI, 0.02-0.04 per 15 minutes of earlier treatment), quality-adjusted life years (increase of 0.29; 95% CI, 0.08-0.49 per 15 minutes of earlier treatment), and EQ-VAS (increase of 1.65; 95% CI, 0.56-2.72 per 15 minutes of earlier treatment). Each 15 minutes of faster door-to-puncture time was associated with higher probability of no or slight problems in each of 5 domains and all domains concurrently (range from 1.86%; 95% CI, 1.14-2.58 for pain or discomfort to 3.55%; 95% CI, 2.06-5.04 for all domains concurrently). Door-to-puncture time less than 60 minutes was associated higher odds of no or slight problems in each domain, ranging from odds ratios of 1.49 (95% CI, 1.13-1.95) for pain or discomfort to 2.59 (95% CI, 1.83-3.68) for mobility, with numbers needed to treat ranging from 7 to 17. Results were similar after multiple imputation of missing data and attenuated when evaluating time from stroke onset. Conclusions and Relevance Results suggest that faster door-to-puncture EVT time was strongly associated with better health-related quality of life across all domains. These results support the beneficial impact of door-to-treatment speed on patient-reported outcomes and should encourage efforts to improve patient-centered care in acute stroke by optimizing in-hospital processes and workflows.